In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare Pvt. Ltd. has announced the groundbreaking ceremony of its Global Collaborative Centre for Medical Countermeasures (GCMC).
The centre, located close to the upcoming international airport in Navi Mumbai, involves an investment of around USD 15 million.
The centre has been acknowledged for its global significance at the second World Local Production Forum organised by the World Health Organization (WHO) in The Hague on November 6-8, 2023.
The objective of GCMC is well aligned to WHO’s call to action, the Coalition for Epidemic Preparedness Innovations’s (CEPI’s) 100 days mission, India’s National Biotechnology Development Strategy (2020-2025), and other key global initiatives.
This facility will serve the needs of both public and private organisations, such as academic institutes, start-ups, MSMEs, and R&D organisations, to provide a comprehensive ecosystem, facilitating the transition from R&D to GMP-scale production for pre-clinical/clinical batches with required regulatory approvals.
GCMC caters to the entire cycle of vaccine development, from strain to supply, biotherapeutics and diagnostics, for both human and veterinary segments, while ensuring sustainable manufacturing. This initiative aligns with the One Health approach, emphasising the interconnection between human, animal and environmental health.
“The current challenges posed in biologics equity arise from the disparity in translational research dissemination from the centres of excellence to the regional manufacturing ‘hub and spoke’ model set-ups. We believe that GCMC would be the needed intervention, strengthening the hubs by providing ‘scaled-up’, regulatory-approved, cost-effective, and free of IP infringement biosolutions sourced from both indigenous research and centres of excellence worldwide,” said Syed S. Ahmed, Director and CEO of TechInvention.
TechInvention Lifecare Pvt. Ltd. is an Indian biotech company that supports the One Health concept by integrating three pivotal interventions: diagnostics, vaccines, and biotherapeutics, catering to both human and veterinary sectors. With a focus on R&D, the company is committed to addressing emerging health challenges.
